Chao Wang

Hunan Reshine New Material Co., Ltd. manufactures primary battery materials. It products include lithium cobalt oxide, lithium manganese oxide, lithium nickel manganese cobalt oxide and lithium iron phosphate. The company was founded in May 2001 and is headquartered in Changsha, China.

Panlin Orient Tianjin Equity Shares Investment LP invests in companies located in China. It targets companies opearting in the fields of technology services, health technology, and consumer services sector. The fund provides financing for early stage capital requirements.

Jiangsu Huashan Environmental Protection Technology Co. Ltd. provides environmental protection services. The company was founded in 1992 and is headquartered in Yixing, China.

Panlin Pingan Tianjin Equity Investment Fund LP invests in companies located in China. The fund targets companies operating in the fields of consumer services, technology services, and health technology sector.

Huaxia Phytorestore Environmental Technology Co. Ltd. provides various services including urban sewage treatment technology, ecological restoration, and wetland technology. The company is based in Huxia, China.

Shanghai Sai'an Biological Medicine Technology Co., Ltd. is a company founded in 2010. Shanghai Sai'an Biological Medicine Technology Co., Ltd. is based in Shanghai, China. It engages in the research, development, and production of pharmaceutical products.

Genfleet Therapeutics (Shanghai), Inc. is a Chinese clinical-stage biotechnology company that focuses on developing novel drug candidates for unmet medical needs in oncology and immunology. The company is based in Shanghai, China, and was founded in 2017 by Jiong Lan and Qiang Lü. The company has built up industry-leading capabilities and expertise in developing both small molecules and biologics since its inception in 2017. Genfleet's proprietary and fully integrated R&D platform highlights multiple cutting-edge products with novel mechanisms and IP. The company's pipeline includes over 10 programs, many of which have entered multi-regional clinical trials across China. Genfleet has completed co-development partnerships with a number of publicly listed companies worldwide. Jiong Lan has been the CEO since 2017.